• Explore /
  • Poster
  • / First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.

First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2): Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17.

Abstract Poster

Authors

null

Michael Thomas Mark

Divison of Oncology/Hematology, Cantonal Hospital Graubünden, Chur, Switzerland

Michael Thomas Mark , Patrizia Froesch , Katrin Gysel , Sacha Rothschild , Alfredo Addeo , Christoph J. Ackermann , Sabrina Chiquet , Martina Schneider , Karin Ribi , Angela Fischer Maranta , Sara Bastian , Roger Anton Fredy Von Moos , Markus Joerger , Martin Früh

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03620669

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr 9088)

DOI

10.1200/JCO.2023.41.16_suppl.9088

Abstract #

9088

Poster Bd #

76

Abstract Disclosures

Similar Posters

First Author: Prantesh Jain

First Author: Nashat Gabrail

First Author: Rachel Frascati

First Author: Stephen V. Liu